Nuvation Bio Inc. (NUVB)
$4.72-3.67%Close
SELLCRISIS · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.6B
- Beta
- 1.62
- P/E (TTM)
- -10.86
- Short % float
- 23.21%
- Days to cover
- 13.9
- SI change
- +1.2%
- 1W
- -3.28%
- 1M
- -20.54%
- vs SPY 1W
- -3.14%
- vs SPY 1M
- -23.04%
Industry peers
FMP comparable companies · ranked by market cap
- EWTXSELLEdgewise Therapeutics, Inc.$4.3BCRISISQ 15$39.57-5.64%
- ABCLBUYAbCellera Biologics Inc.$3.9BCRISISQ -6$12.83-0.24%
- VERASELLVera Therapeutics, Inc.$2.2BCRISISQ 20$30.25-3.35%
- VRDNSELLViridian Therapeutics, Inc.$2.1BCRISISQ -3$18.28-0.44%
- AUPHSELLAurinia Pharmaceuticals Inc.$2.1BRECOVERYQ 22$16.01-1.15%
- CLDXSELLCelldex Therapeutics, Inc.$2.0BCRISISQ 5$30.43-4.01%
- QURESELLuniQure N.V.$1.6BCRISISQ 16$23.14-2.56%
- OCULSELLOcular Therapeutix, Inc.$1.6BCRISISQ 3$7.23-4.23%
- GPCRSELLStructure Therapeutics Inc.$1.5BCRISISQ 12$26.68-6.69%
- JANXBUYJanux Therapeutics, Inc.$1.1BRECOVERYQ 11$17.92-5.34%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on NUVB?
- LOPJLB’s latest quantitative signal on Nuvation Bio Inc. (NUVB) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is NUVB in?
- Nuvation Bio Inc. (NUVB) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Nuvation Bio Inc. (NUVB) do?
- Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective…